Vedanta Granted Four U.S. Patents for Therapeutics Based on Beneficial Gut Bacteria

Vedanta Granted Four U.S. Patents for Therapeutics Based on Beneficial Gut Bacteria
Vedanta Biosciences has recently been granted four U.S. patents covering pharmaceutical compositions of therapeutics targeting inflammatory bowel disease (IBD) and other  immune-mediated and infectious conditions. The new patents protect Vedanta’s therapeutic candidates in development for the treatment of IBD, food allergies, and other autoimmune and infectious diseases. One of Vedanta’s lead investigational candidates, VE303, in development for the treatment of recurrent
Subscribe or to access all post and page content.